Compare Cigna Corp (CI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs GeneDx Holdings Corp — how do they compare? Cigna Corp trades at $273.93 (market cap $73.56B), while GeneDx Holdings Corp trades at $82.41 (market cap $2.44B). The key difference: Cigna Corp is far larger — about 30.1× GeneDx Holdings Corp's market cap, and Cigna Corp pays a 2.24% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CI | WGS | |
|---|---|---|
Market Cap | $73.56B | $2.44B |
Sector | Health | Technology |
52-Week High | $311.00 | $167.51 |
52-Week Low | $244.41 | $34.51 |
Enterprise Value | $98.27B | $2.48B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $278.40, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.51 and ROE of 15.49%. Recent Q2 2026 earnings beat expectations at $7.78 per share, and the company raised its full-year EPS guidance. The stock is supported by consistent dividend payments and robust cash flow from operations of $9.60 billion in 2025.
The outlook is positive with a consensus price target of $338.90, implying 22% upside. Key opportunities include steady earnings growth and capital returns, while risks involve healthcare cost pressures and competitive dynamics. Analyst sentiment is strongly bullish with 73.68% buy ratings, though technical indicators suggest near-term caution.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
